ESH 2024

2024-05-31 - 2024-06-03
Berlin, Germany

EAS 2024

2024-05-26 - 2024-06-29
Lyon, France

ACC 2024

2024-04-06 - 2024-04-08
Atlanta, United States

ESC 2023

2023-08-25 - 2023-09-28
Amsterdam, Netherlands

ESH 2023

2023-07-23 - 2023-07-26
Milan, Italy

EAS 2023

2023-05-21 - 2023-05-24
Berlin, Germany

ACC 2023

2023-03-04 - 2023-03-06
New Orleans, LA, United States

ESC 2022

2022-08-26 - 2022-09-29
Barcelona, Spain

ESH 2022

2022-06-17 - 2022-06-20
Athen, Greece
Search in Scientific Content:
Date
Filters:
Overview o
2:48

Overview of the 2024 EAS Congress

Presenter: Kausik K Ray
Specialty: Atherosclerosis
EAS 2024
Controllin
15:57

Controlling the uncontrollable - resistant hypertension and the role of aldosterone

Presenter: Michel Azizi
Specialty: Hypertension
ESH 2024
Management
7:31

Management of older hypertensive patients

Presenter: Athanase Benetos
Specialty: Hypertension
ESH 2024
ESH guidel
17:54

ESH guidelines 2023: a new light on beta-blockers in hypertension

Presenter: Giuseppe Mancia
Specialty: Hypertension
ESH 2024
ESH - ESC
13:49

ESH - ESC HFA Joint meeting: HFpEF update 2024

Presenter: Enrico Agabiti Rosei
Specialty: Hypertension
ESH 2024
2023 ESH H
6:23

2023 ESH Hypertension Guideline Update

Presenter: Rosa de Pinho
Specialty: Hypertension
ESH 2024
Combinatio
14:49

Combination of a beta-blocker with calcium channel blocker in hypertension

Presenter: Gianfranco Parati
Specialty: Hypertension
ESH 2024
ESH Clinic
7:42

ESH Clinical Practice Guidelines

Presenter: Roland Schmieder
Specialty: Hypertension
ESH 2024
Nephroprot
6:24

Nephroprotection using SGLT2 inhibitors in patients with hypertension

Presenter: Michael Böhm
Specialty: Hypertension
ESH 2024
Diabetes a
7:14

Diabetes and Metabolic risk factors

Presenter: Josep Redon
Specialty: Hypertension
ESH 2024
Beta-block
13:47

Beta-blockers in hypertension and CVD

Presenter: Ricardo Fontes-Carvalho
Specialty: Hypertension
ESH 2024
ESH - ISH
8:37

ESH - ISH Joint Session: Balancing common side effects of Thiazide/Thiazide-like diuretics through addition of other Blood Pressure lowering drugs

Presenter: Jorie Versmissen
Specialty: Hypertension
ESH 2024
How lifest
5:12

How lifestyle affects hypertension

Presenter: Fadi Charchar
Specialty: Hypertension
ESH 2024
Overcoming
4:21

Overcoming the resistance - Is renal denervation the solution?

Presenter: Konstantinos Tsioufis
Specialty: Hypertension
ESH 2024
Hypertensi
14:50

Hypertension and beta-blocker choice: influence of age, stress, and co-morbidities

Presenter: Sverre Erik Kjeldsen
Specialty: Hypertension
ESH 2024
Effect of
7:31

Effect of renal denervation on blood pressure in patients with chronic kidney disease and uncontrolled hypertension

Presenter: Roland Schmieder
Specialty: Hypertension
ESH 2024
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
HOPE 4 - I
5:19

HOPE 4 - Impact on cardiovascular risk of a community based multifaceted intervention in individuals with hypertension in 2 middle income countries: The Heart Outcomes Prevention and Evaluation 4 study

Presenter: J.D. Schwalm
SYNTAXES:
7:28

SYNTAXES: Ten-Year Survival after Coronary Artery Bypass Grafting versus Percutaneous Coronary Intervention: The SYNTAX Extended Survival study

Presenter: Daniel Johannes Franciscus Maria Thuijs
MITRA-FR -
8:46

MITRA-FR - 2 years follow-Up of the MITRA-FR study a randomized controlled trial evaluating the effectiveness of percutaneous mitral valve repair in secondary mitral regurgitation

Presenter: Jean-Francois Obadia
DAPA HF Th
6:20

DAPA HF The Dapagliflozin And Prevention Of Adverse-outcomes In Heart Failure Trial

Presenter: John McMurray
CONDI-2/ER
4:010

CONDI-2/ERIC-PPCI Effect of remote ischemic conditioning on clinical outcomes in patients with Stsegment elevation myocardial infarction undergoing primary percutaneous coronary intervention

Presenter: Hans Erik Botker
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Once-weekl
1:17

Once-weekly semaglutide in people with HFpEF and obesity

Presenter: Mikhail Kosiborod
Should ABP
1:31

Should ABPM parameters have a role in clinical practice?

Presenter: Paolo Palatini
On the mos
1:09

On the most important key points on the diagnosis of Hypertension in the new ESH2023 guidelines

Presenter: Bryan Williams
2023 ESC G
1:13

2023 ESC Guidelines for the Management of Endocarditis

Presenter: Michael A. Borger
How to mea
1:37

How to measure blood pressure in the very obese patients?

Presenter: Paolo Palatini
The keypoi
1:14

The keypoints of 2023 ESC Guidelines for the Management of Cardiomyopathies

Presenter: Juan Pablo Kaski
How to bes
1:20

How to best perform office blood pressure management?

Presenter: Paolo Palatini
Key points
1:09

Key points from the newly updated ESC Heart Failure guidelines

Presenter: Marco Metra
Do overwei
0:54

Do overweight and obesity confer an additional risk of CAD in patients with FH?

Presenter: Amany Elshorbagy